Marksans Pharma
Marksans Pharma Share Price

Marksans Pharma Share Price

NSE: MARKSANS

|

BSE: 524404

|

Pharmaceuticals

100% Buy

₹254.55

-₹2.20 (-0.86%) Last updated on 11 Jul, 2025 | 15:59 IST

Marksans Pharma Overview

Market cap
Market Cap Switch₹11,535 Crs
Open
₹256.95
Prev. Close
₹256.75
Circuit range
₹305.45 - ₹203.65
Day range
₹253.50 - ₹266.00
Year range
₹171.00 - ₹358.70
Volume
12,43,743
Avg. traded
₹259.16
Revenue (12m)
₹2,623 Crs

About Marksans Pharma

Marksans Pharma Limited is a pharmaceutical company headquartered in Mumbai. Its primary focus is on over-the-counter (OTC) and prescription drugs with diverse applications in fields such as oncology, gastroenterology, antidiabetic, antibiotics, cardiovascular, pain management and gynaecology.

The market capitalisation of Marksans Pharma is over ₹7,300 crore as of January 11, 2024. Marksans Pharma share price has gained over 160% in the last three years.

Business operations

Marksans Pharma focuses on the distribution of pharmaceutical products and is actively involved in research and development (R&D). It provides contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The company’s R&D capabilities include dossier development services, formulation development and specialised drug delivery systems.

In the domestic market, the company’s speciality division concentrates on oncology and critical care therapy, with Markparin and Epigrof being its most popular brands. Epigrof is also supplied to hospitals and other institutes specialising in burns and trauma care. The company has a cerebella division that specialises in marketing drugs for lifestyle diseases, neurology and psychiatric therapy.

Its primary markets include the US, Europe, Canada, Australia and emerging markets such as Southeast Asia, Africa, Latin America and Russia. Its product portfolio consists of over 500 registered products in these regions. These international operations have grown over the years due to mergers and acquisitions by the company.

Marksans Pharma acquired Nova Australasia Pty Ltd. (Nova) in 2005. Nova is an Australian marketing company specialising in the promotion of over-the-counter and pharmaceutical products. Following this, in 2008, Marksans expanded its portfolio through the acquisition of the UK's Hale Group, inclusive of its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell). In the same year, the company acquired Relonchem Ltd. This company is actively involved in the licensing, marketing and distribution of generic pharmaceutical products in the UK.

The company has a portfolio of more than 50 FDA-approved products. In the UK, it offers a diverse range of over 100 products under the Bells Healthcare brand and another 160 products under its Relonchem brand.

Marksans Pharma operates three manufacturing units located in different regions: Goa, the UK and the USA. In Farmingdale, USA, the company can produce 6 billion tablets and hard capsules annually. Meanwhile, the Southport unit in the UK contributes to the production of 2 billion bottles, 1 billion tubes and 1 billion sachets per year. In Goa, the manufacturing capabilities include 2.4 billion softgel and hard gelatin capsules annually, along with the production of 6 billion solid tablets per year. The plant in Goa is spread over 18,000 square metres.

In addition to its manufacturing facilities, Marksans Pharma Limited has four research and development (R&D) centres located in Goa, Navi Mumbai, the UK and the USA.

Financial Highlights

– Marksans Pharma’s revenue from operations for FY23 stood at ₹1,852 crore, up by 24.2% compared to ₹1,491 crore in FY22. – The net profit after tax for FY23 was ₹265.3 crore compared to ₹186.8 crore during the previous year. – In FY23, EBITDA increased to ₹339.3 crore from the previous year's ₹258.9 crore. – The company's earnings per share (EPS) stood at ₹6.4 in FY23 compared to ₹4.5 in the previous financial year.

  • Chart
  • Fundamentals
  • Financials
  • Shareholdings
  • Events
  • Peers
  • News
  • FAQs

Marksans Pharma Share Price Chart

Please wait...

Marksans Pharma Key Indicators

P/E ratio
30.3
P/B ratio
4.74
ROE
11.46%
ROCE
14.81%
Dividend yield
0.31%
Debt/Equity ratio
EPS
2.95

Investment Checklist: (4/6)

passed

Equity returns

not passed

Dividend returns

not passed

Safety factor

passed

Growth factor

passed

Debt vs Equity

passed

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst Ratings:

Buy

Buy

100%

Hold

0%

Sell

0%

This analysis is based on the reviews of 2 experts in the last 7 days

Marksans Pharma Financial Ratios

  • Profitability

  • Operational

  • Valuation

Operating profit margin

23.61%

Net profit margin

15.63%

ROE

11.46%

ROA

9.17%

ROCE

14.81%

Marksans Pharma Shareholder returns

1 day
-0.86%
1 week
-3.23%
1 month
-3.41%
3 months
+23.82%
1 year
+32.33%
3 years
+414.24%
5 years
+655.34%

Revenue Statement

All values are in ₹ Crores (Cr)
RevenueNo Sort
Operating ProfitNo Sort
Net ProfitNo Sort
Mar-24
2,177.41
509.00
314.89
Mar-23
1,852.14
398.63
265.32
Mar-22
1,490.84
300.73
186.81
Mar-21
1,376.18
346.30
238.54

Cash Flow

All values are in ₹ Crores (Cr)
OperatingNo Sort
InvestingNo Sort
FinancingNo Sort
Mar-24
230.41
-140.84
-68.73
Mar-23
237.41
-259.21
197.83
Mar-22
99.26
-84.39
79.51
Mar-21
178.59
-44.85
-15.29

Balance Sheet

All values are in ₹ Crores (Cr)
Total AssetNo Sort
Total LiabilityNo Sort
Mar-24
2,680.95
595.05
Mar-23
2,190.39
425.32
Mar-22
1,660.11
437.14
Mar-21
1,228.02
322.67

Marksans Pharma Share Price History

DayOpenCloseChange %
11-Jul-25
₹256.95
₹254.55
-0.86%
10-Jul-25
₹259.00
₹256.75
-0.81%
09-Jul-25
₹253.05
₹258.85
+2.54%
08-Jul-25
₹257.50
₹252.45
-1.92%
07-Jul-25
₹263.30
₹257.40
-2.15%
04-Jul-25
₹260.05
₹263.05
+1.37%
03-Jul-25
₹258.20
₹259.50
+0.84%
02-Jul-25
₹258.00
₹257.35
-0.44%

Marksans Pharma Shareholding Pattern

CategoryDec 2024Sep 2024Jun 2024Mar 2024
Promoters
43.87%
43.87%
43.87%
43.85%
Foreign institutions-FII
21.95%
21.31%
18.59%
15.57%
Other domestic institutions
1.16%
1.08%
0.93%
0.94%
Retail and other
29.87%
30.71%
33.78%
35.40%
Mutual Funds
3.15%
3.02%
2.82%
4.23%

Corporate Actions

  • Dividend • ₹0.6/share

    Ex date 17 Sep 2024

    expand tab

Stocks Similar to Marksans Pharma

PriceNo Sort
Change %No Sort
Alembic₹117.26-₹1.46 (-1.23%)
Amrutajan Health₹726.40-₹9.85 (-1.34%)
Gufic Biosciences₹349.90-₹1.30 (-0.37%)
Hester Biosciences₹1,800.00+₹5.50 (0.31%)
Morepen Labs₹62.67-₹0.80 (-1.26%)
Neuland Lab₹12,301.00+₹421.00 (3.54%)
Unichem Laboratories₹590.25-₹7.15 (-1.2%)

Popular Stocks

PriceNo Sort
Change %No Sort
IDFC First Bank₹75.23-₹1.40 (-1.83%)
Indian Railway Finance Corp₹135.28-₹1.85 (-1.35%)
ITC₹416.80-₹0.05 (-0.01%)
JIO FIN SERVICES LTD₹325.80-₹5.85 (-1.76%)
Suzlon₹65.92-₹0.05 (-0.08%)
Tata Motors₹681.80-₹13.80 (-1.98%)
Tata Power₹396.85-₹3.05 (-0.76%)
Tata Steel₹159.84-₹0.82 (-0.51%)
Trident₹31.70-₹0.39 (-1.22%)
Wipro₹258.30-₹6.75 (-2.55%)

FAQs on Marksans Pharma

What is the share price of Marksans Pharma today?

chevron-up
Marksans Pharma share price is ₹ 254.55 as on 11 Jul, 2025 | 15:59 IST.

What are the high & low stock price of Marksans Pharma today?

chevron-up
Marksans Pharma stock price hit a high of ₹ 266.00 and low of ₹ 253.50 as on 11 Jul, 2025 | 15:59 IST.

What is the market cap of Marksans Pharma?

chevron-up
The market cap of Marksans Pharma is ₹ 11,535.28 Crores as on 11 Jul, 2025 | 15:59 IST.

What are the the 52-week high and low share prices of Marksans Pharma stock on the NSE?

chevron-up
52-week high stock Price of Marksans Pharma is ₹ 358.70 and Low Price is ₹ 171.00 as on 11 Jul, 2025 | 15:59 IST.

What are the stock symbols of Marksans Pharma?

chevron-up
The stock symbol of Marksans Pharma is NSE: MARKSANS on the NSE, BSE: 524404 on the BSE, and the ISIN is INE750C01026.

Can I buy Marksans Pharma shares on Holidays?

chevron-up
No, shares of Marksans Pharma or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Marksans Pharma shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.

What is the PE and PB ratio of Marksans Pharma?

chevron-up
The PE and PB ratio of Marksans Pharma is 30.3 and 4.74 respectively, as on 11 Jul, 2025 | 15:59 IST.

What are the returns on Marksans Pharma shares?

chevron-up
The historical returns for Marksans Pharma shares are 32.33 for 1 year, 414.24 for 3 year and 655.34 for 5 year.